A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma

British Journal of Haematology

Volumn 93, Issue 4, 1996, Pages 931-934

  Cook, G ^a   Sharp, R A ^a   Tansey, P ^a   Franklin, I M ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

multiple myeloma; neutropenia; out patient; paraprotein response; Z Dex

Indexed keywords

DEXAMETHASONE; IDARUBICIN; UNCLASSIFIED DRUG; Z DEX;

ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTIPLE MYELOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0029942953     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1715.x     Document Type: Article

References (12)

1. Alexanian, R. (1986) High-dose glucocorticoid therapy for resistant multiple myeloma. Annals of Internal Medicine, 105, 8-11.
2. Anderson, H., Scarffe, J.H., Ranson, M., Young, R., Wieringa, G.S., Morgenstren, G.R., Fitzsimmons, L. & Ryder, D. (1995) VAD chemotherapy as remission induction for multiple myeloma. British Journal of Cancer, 71, 326-330.
3. Attal, M., Huguei, F. & Schlaifer, D. (1992) Intensive combined therapy for previously untreated aggressive myeloma. Blood, 79, 1130-1136.
4. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 1353-1356.
5. Boccadoro, M. & Pileri, A. (1992) Standard chemotherapy for myelomatosis: an area of great controversy. Hematology/Oncology Clinics of North America, 6, 371-382.
6. Chisesi, T., Capnist, G., De Dominicis, E. & Dini, E. (1988) A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced multiple myeloma. European Journal of Cancer and Clinical Oncology, 24, 681-684.
7. Gore, M.E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P.J., Clark, P.I., Millar, B., Maitland, J.A., Judson, T.R., Tillyer, C., Malpas, C. & McElwain, T. (1989) Intensive treatment of multiple myeloma and criteria for complete response. Lancet. ii, 879-885.
8. Lopez, M., Lazzaro, B., Di Lanzo, L., Papaldo, P., Ganzina, F. & Di Pietro, N. (1985) Activity of oral 4-demethoxydaunorubicin in non-Hodgkin's lymphoma. 14th International Congress of Chemotherapy, Kyoto, Japan, p. 39.
9. MacLennan, J.C.M. & Cusick, J. (1985) Objective evaluation of the role of vincristine in the induction and maintenance therapy for myelomatosis. British Journal of Cancer, 52, 153-158.
10. Majolino, I., Scime, R., Indovina, A., Vasta, S., Fabbiano, F., Majrin, S., Hanser, D., Gentile, S., Santero, A. & Felke, R. (1990) Autologous blood stem cell transplantation in haematological malignancies. Acta Haematologica, Suppl. 1, 74-78.
11. Samson, D., Newland, A., Kearney, J., Joyer, M., Mitchell, T. & Barret, J. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, ii, 882-885.
12. Woodruff, R. (1981) Treatment of multiple myeloma. Cancer, 8, 225-270.